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Abstract Parkinson’s disease is a neurodegenerative
disorder characterized by severe motor deﬁcits mainly due
to degeneration of dopaminergic neurons in the substantia
nigra. Decreased levels of the cell’s most important anti-
oxidant, glutathione, have been detected in nigral neurons
of Parkinson patients, but it is unknown if they are the
cause or merely the consequence of the disease. To eluci-
date if glutathione depletion causes selective degeneration
of nigral dopaminergic neurons, we down-regulated glu-
tathione synthesis in different brain areas of adult rats by a
viral vector-based RNAi approach. Decreased glutathione
synthesis resulted in progressive degeneration of nigral
dopaminergic neurons, while extra-nigral and striatal neu-
rons were signiﬁcantly less vulnerable. Degeneration of
dopaminergic neurons was accompanied by progressive
protein aggregate formation and functional motor deﬁcits
and was partially rescued by a-synuclein. That the survival
of nigral dopaminergic neurons depends on the precise
control of glutathione levels was further demonstrated by
signiﬁcant degeneration induced through moderate over-
production of glutathione. Over-expression of either of the
two subunits of glutamate–cysteine ligase induced aberrant
glutathiolation of cellular proteins and signiﬁcant degen-
eration of dopaminergic neurons. Thus, while glutathione
depletion was demonstrated to be a selective trigger for
dopaminergic neuron degeneration, a glutathione replace-
ment approach as a potential treatment option for
Parkinson’s patients must be considered with great care. In
conclusion, our data demonstrate that survival of nigral
dopaminergic neurons crucially depends on a tight regu-
lation of their glutathione levels and that the depleted
glutathione content detected in the brains of Parkinson’s
disease patients can be a causative insult for neuronal
degeneration.
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Abbreviations
AAV-2 Adeno-associated virus serotype 2
DA Dopamine
EGFP Enhanced green ﬂuorescent protein
GCL-c Catalytic subunit of glutamate-cysteine ligase
GCL-m Modulatory subunit of glutamate-cysteine
ligase
GSH Glutathione, reduced state
GSSG Oxidized glutathione
GSX Total glutathione
shRNA Small helical RNA
TH Tyrosine hydroxylase
PD Parkinson’s disease
VMAT-2 Vesicular mono amine transporter 2
Introduction
Degeneration of nigral dopaminergic (DA) neurons is a
major hallmark of Parkinson’s disease (PD), resulting in
striatal dopamine loss and inappropriate ﬁne tuning of
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the disease due to familial mutations while the vast
majority of cases are sporadic. No singular pathomecha-
nism initiating PD has been identiﬁed so far. Current
hypotheses encompass oxidative stress through mitochon-
drial dysfunction, accumulation of transition metals,
dysfunction of protein folding quality control, inﬂamma-
tion, and depletion of neurotrophic support or of anti-
oxidant defence mechanisms [34]. Depletion of the major
cellular anti-oxidant glutathione (GSH) has been described
in several independent studies to take place speciﬁcally in
the substantia nigra of PD patients [27, 28, 30]. GSH
depletion is not detected in patients with multiple system
atrophy or progressive supranuclear palsy, despite the
degeneration of dopaminergic neurons [29, 33]. In inci-
dental Lewy body disease, which may be considered as a
pre-symptomatic form of PD [16] and is present in up to
10% of individuals over the age of 60, GSH depletion is
already present in the substantia nigra [18], and thus
appears to precede complex I dysfunctions, iron accumu-
lation and striatal dopamine loss [38]. These ﬁndings imply
decreased GSH levels being an early event in PD aetiology,
possibly initiating or facilitating a cascade of further oxi-
dative stress lesions. This view is supported by in vitro and
in vivo studies demonstrating that GSH depletion induces
oxidative damage to complex I proteins [3, 4].
GSH is a tri-peptide consisting of the amino acids glu-
tamate, cysteine and glycine, the reactive thiol group of the
cysteine residue serving as the cells most effective anti-
oxidant. The rate-limiting step in GSH synthesis is carried
out by glutamate–cysteine ligase (GCL), a dimeric protein
composed of a catalytic (GCLc) and a modulatory subunit
(GCLm). The modulatory subunit serves to increase the
afﬁnity of the catalytic subunit for its substrate glutamate,
and renders the holo-enzyme less sensitive to feedback
inhibition by GSH. Astrocytes synthesize the vast majority
of brain GSH and secrete the peptide, but neurons can take
up only the precursors derived from extra-cellular catabo-
lism and must synthesize their own GSH. In non-enzymatic
reactions GSH detoxiﬁes NO2 and peroxynitrite, and enzy-
matically reduces other anti-oxidants as dehydroascorbate
and, indirectly, tocopherol and through glutaredoxin main-
tains sulfhydryl groups of proteins in reduced states. GSH
peroxidases use GSH for enzymatic reduction of hydrogen
peroxide. Oxidized GSH (GSSG) is recycled into the
reduced state by GSH-reductase (GSR) [25].
Whether GSH depletion can be a selective trigger spe-
ciﬁcally for DA neuron degeneration has not yet been
demonstrated experimentally. We thus down-regulated
GSH synthesis by viral vector-mediated RNA interference
in DA and in non-DA neurons of the adult rat brain. We
could demonstrate that depletion of anti-oxidative defence
serves as an initiator for progressive DA neuron degener-
ation, including protein aggregation and functional motor
deﬁcits, while non-DA neurons were signiﬁcantly less
vulnerable to GSH depletion-induced degeneration.
Dopaminergic neuron degeneration was partially prevented
by a-synuclein, a synaptic vesicle-associated protein which
forms the major protein component of Lewy bodies, the
aggregation entities found in postmortem brains of PD
patients [12]. Unexpectedly, over-expression of either of
the two subunits of GCL also induced signiﬁcant degen-
eration of DA neurons, emphasizing that GSH levels must
be maintained within a tightly controlled range and sug-
gesting that GSH substitution as a neuroprotective strategy
for PD may pose severe risk.
Methods
shRNAs
ShRNAs were selected using the DEQOR algorithm [13]t o
target (1) rat glutamate–cysteine ligase catalytic subunit
(GCLc, E.C. 6.3.2.2); (2) rat glutamate–cysteine ligase
modulatory subunit (GCLm); and (3) rat glutathione
reductase (GSR, E.C. 1.8.1.7). Control shRNAs were:
EGFP-shRNA, Luciferase-shRNA and scrambled shRNA
(Dharmacon-shRNA). Detailed sequences are given in
Supplemental Methods. All shRNAs were tested for efﬁ-
ciency of target downregulation in a transient co-
transfection approach as described [23] and resulted in at
least 80% of target mRNA downregulation.
AAV vectors
Recombinant vector backbones were constructed so that
expression of all shRNAs was driven by the human H1
polymerase III promoter, while expression of the EGFP
reporter or of a-synuclein was driven by the human syn-
apsin 1 gene promoter [20], both expression cassettes being
in a head-to-head arrangement. The EGFP expression cas-
sette also contains a WPRE for enhanced mRNA stability
and a human bovine growth hormone polyadenylation site.
While EGFP expression was entirely neuron-restricted by
the hSYN promoter, the H1 promoter is putatively active in
all cell types. We ruled out that recombinant AAV-2 vectors
would result in astrocyte transduction and concomitant
expression of shRNAs in these cells, potentially leading to
diminished supply of GSH precursors from astrocytes to
neurons by constructing an AAV-2 vector driving EGFP
expression from an astrocyte-speciﬁc GFAP promoter.
Injection of this virus into the substantia nigra resulted in
EGFP expression in no more than 5–10 astrocytes per whole
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123midbrain, thus conﬁrming the neuron-speciﬁc targeting
approach (not shown).
Recombinant vectors were prepared as described [24],
puriﬁed by iodixanol step gradient, heparin sulphate afﬁnity
chromatography and dialysis before stored frozen at -80C
in single-use aliquots. Vector genomes were titrated by
quantitative PCR. The purity of the preparations was con-
ﬁrmed by SDS gel electrophoresis and silver staining.
Animal procedures
All experimental animal procedures were conducted
according to approved experimental animal licenses
issued by the responsible animal welfare authority
(Niedersa ¨chsisches Landesamt fu ¨r Verbraucherschutz und
Lebensmittelsicherheit) and controlled by the local animal
welfare committee of the University Medical Center
Goettingen. Intracerebral stereotaxic injections into the
substantia nigra (coordinates relative to bregma = AP,
-5.3; ML, ?2.2; DV, -7.7 mm) and striatum (coordinates
AP, ?1.2; ML, ?2.3; DV, -5.0 mm) of 2.5-month-old
female Wistar rats, maintenance of animals and killing and
perfusion were performed essentially as described [32].
Two microliter of AAV in PBS containing 4 9 10
9 vector
genomes were injected at a speed of 500 nl/min. This
application resulted in transduction of 70–75% of nigral
DA neurons as judged by EGFP/TH co-labelling (not
shown). For numbers of animals used for each individual
group please see Table 1 in Supplemental Information.
Functional/behavioural analysis of nigro-striatal
projection
Apomorphine-induced circling behaviour was analysed
essentially as described for 6-OHDA lesioned rats [31].
Speciﬁcally, animals were placed into cylindrical, ﬂat-
bottomed chambers of 40 cm diameter, injected i.p. with
0.4 mg apomorphine/kg body weight and their turning
behaviour recorded with a video camera for ofﬂine analy-
sis. Only complete turns of 360C were counted.
Quantiﬁcation of GSH
The glutathione quantiﬁcation assay is based on the 96-
well microplate assay previously reported by Dringen [10].
Details of the procedure are given in Supplemental
Methods.
Cell viability assay
Cell viability was measured in 96-well plates using the
WST-1 assay according to the protocol provided by the
manufacturer (Roche Diagnostics, Germany).
Immunohistochemistry
Details are given in Supplemental Methods.
Thioﬂavin-S staining
EGFP ﬂuorescence present in the tissue was eliminated by
microwave boiling of mounted sections (5 min in 10 mM
Na-Citrate, pH 6.0, 0.05% Tween 20; cooled to RT slowly
in ca. 1 h) in order to avoid interference with emitted Thio-
S ﬂuorescence. Sections were washed in PBS (10 min), in
water (5 min), incubated in 0.05% Thio-S in 50% EtOH
(ﬁltered through 0.22 lm) for 20 min, washed 3 9 5 min
in 80% EtOH, then 3 9 10 min and 1 9 30 min in PBS
followed by immunohistochemistry as outlined in Supple-
mental Methods. Due to the broad emission spectrum of
Thio-S we used only Cy 5-coupled secondary antibodies in
order to avoid any possible overlap of emission spectra.
Dopamine measurement
Animals were killed by decapitation and their brains
quickly removed. Both striata were prepared individually
and quick-frozen on dry ice. 143 ll perchloric acid 70%
was added per 50 mg of sample and the mixture homog-
enized by mechanical beads (Precellys 24 homogenizer)
and centrifuged twice. 20 ll of the resulting supernatant
was then analysed by HPLC with electrochemical detection
as described [19].
Statistics
For statistics, the respective groups were evaluated by one-
way ANOVA with Bonferroni’s multiple comparison test
using GraphPad Prism. Differences between groups were
considered statistically signiﬁcant if p\0.05. Signiﬁ-
cances are indicated with *p\0.05, **p\0.01,
***p\0.001. All data are presented as mean ± standard
deviation (SD) unless otherwise indicated.
Results
Silencing expression of the catalytic or the modulatory
subunit of glutamate–cysteine ligase induces gradual
and progressive degeneration of nigral DA neurons
In order to silence glutathione synthesis in neurons of the
rat brain, we constructed AAV-2 vectors expressing the
ﬂuorescent reporter protein EGFP plus the respective
shRNA. Functional veriﬁcation of the various vectors was
performed in cultured primary neurons (see supplemental
data for detailed information), since quantiﬁcation of GSH
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123levels on a per neuron basis could not be performed in
tissue samples due to the overriding GSH content of
astrocytes. In vitro experiments showed a direct correlation
between the extent of decreasing GSH levels and impaired
cell viability (Suppl. Fig. 1), proving functionality and
speciﬁcity of our approach. In vivo, we ﬁrst conﬁrmed that
continuous expression of shRNAs per se did not impact
substantially on the survival of nigral DA neurons (Suppl.
Fig. 2). Next, we investigated the loss of DA neurons in the
substantia nigra of adult rats due to silencing of glutathione
synthesis or recycling. DA neuron numbers were quantiﬁed
by TH and VMAT2 immunohistochemistry, and loss of
neurons was also conﬁrmed by NeuN immunohistochem-
istry (Suppl. Fig. 3). In comparison to expression of the
three different control shRNAs, we found a progressive
decline in DA neuron numbers after expression of shRNAs
targeting the catalytic subunit of glutamate–cysteine ligase
(GCLc). At 3, 6 and 9 weeks after vector injections,
expression of GCLc-shRNA#2 resulted in loss of 20, 35
and 57% of DA neurons as compared to control shRNAs,
while expression of GCLc-shRNA#3 resulted in loss of 6,
21 and 25% of DA neurons (Fig. 1a; Table 1 in Supple-
ment). These data correlate well with the potency of the
respective shRNA to decrease GSH levels and to impair
viability in vitro (Suppl. Fig. 1). Also in agreement with in
vitro data was the ﬁnding that targeting glutathione
reductase (GSR) did not result in any signiﬁcant loss of
nigral DA neurons when compared to expression of the
control shRNAs.
In order to evaluate if downregulation of the modulatory
subunit of GCL might also result in degeneration of DA
neurons, we expressed two different shRNAs targeting
GCLm, and achieved moderate but signiﬁcant loss of DA
neurons at 9 weeks after transduction of 29 and 18%,
respectively, compared to control shRNAs. As for GCLc,
cell counts for TH and VMAT resulted in almost identical
numbers (Fig. 1b, c).
These results demonstrated that targeting GSH produc-
tion by silencing the expression of GCLc or GCLm is
sufﬁcient to induce a slowly progressive loss of nigral DA
neurons, whereas targeting GSH recycling by silencing the
expression of GSR is insufﬁcient to induce such neuronal
loss.
Depleted GSH synthesis causes progressive motor
imbalance
Next, we analysed impairments of motor control induced
by the targeting of GSH synthesis in order to evaluate if
DA neuron loss could be documented by behavioural tests.
The DA agonist apomorphine induces contralateral rotation
behaviour in animals with unilateral de-afferentiation of
nigral DA neurons, whereas ipsilateral rotations in
unilateral lesions are mainly due to loss of striatal termini
of DA neurons. Already 3 weeks after the expression of the
GCLc-shRNA#2, at a time when there is only minor DA
neuron loss in the SNpc, a signiﬁcant preference for turning
towards the ipsilateral side was evident (Fig. 2a). Both
frequency and duration of ipsilateral rotations increased
through the course of the experiment, while we detected no
signiﬁcant preference for turning behaviour at any time
after expression of the control shRNA. After analysis of
rotation behaviour at 9 weeks, the animals were killed and
ipsilateral and contralateral striata were quantiﬁed for their
content of DA and its metabolites DOPAC and HVA
(Fig. 2b). After expression of GCLc-shRNA#2, DA levels
were found to be reduced to 55% in ipsilateral versus
contralateral striatum. Levels of metabolites were found to
be reduced to only about 80%, indicating a higher rate of
Fig. 1 Silencing of glutathione synthesis induces progressive degen-
eration of nigral dopaminergic neurons in the adult rat brain. a AAV
vectors expressing either one of three different control shRNAS (for
details see Suppl Fig 1), a shRNA targeting glutathione reductase
(GSR), or either one of two shRNAs targeting the catalytic subunit of
glutamate–cysteine ligase (GCLc) were injected into rat SNpc;
dopaminergic neurons were counted by TH and VMAT2 immuno-
histochemistry at 3 weeks (light grey bars), 6 weeks (dark grey bars)
and 9 weeks (black bars) after transduction. Quantiﬁcation of
surviving DA neurons in SNpc at 9 weeks after targeting the
modulatory subunit of glutamate–cysteine ligase (GCLm) with two
different shRNAs is shown in b for TH immunohistochemistry and
c for VMAT-2 immunohistochemistry, exemplarily demonstrating
equal cell numbers with both stains. Bars mean ± SD
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123DA metabolism in these brains, as exempliﬁed by a sig-
niﬁcantly enhanced striatal DA turnover rate (DOPAC/
DA = 0.29 ± 0.04 for controls, but 0.42 ± 0.06 after
GCLc-shRNA#2 expression; p\0.05). Expression of
control shRNA did not result in any decrease of DA or
metabolites.
Nigral DA neurons are more vulnerable to GSH
depletion than extranigral or striatal neurons
All shRNA-expressing viral vectors used in this study also
express EGFP as a reporter protein. This allowed us to
monitor neuronal transduction and survival independently
from cell type speciﬁc markers. Injection of AAV-2 vectors
into the substantia nigra demonstrated some preference for
transduction of DA neurons, but transduced neurons were
also readily detected dorsally (in the parabrachial pig-
mented nucleus) and ventrally (in the pars reticulata) to the
pars compacta (Fig. 3a, b). Neurons transduced outside the
pars compacta appeared to be morphologically fully intact
after 9 weeks of expression of GSH-targeting shRNAs (see
insets in Fig. 3a, b). When counting EGFP?/TH- neurons
in sections with similar rostro-caudal position at 9 weeks
after expression of control or GSH-targeting shRNAs, we
found no difference in cell numbers (Fig. 3c), suggesting a
selective vulnerability of DA neurons to GSH depletion.
We also injected vectors encoding control shRNA or
shRNA targeting GCLc (GCLc-shRNA#2) into the stria-
tum and recorded EGFP ﬂuorescence at 9 weeks after
transduction. We counted 2,148 ± 468 EGFP-positive
neurons per mm
2 in control and 1,799 ± 352 EGFP-posi-
tive neurons per mm
2 in GCLc-shRNA expressing brains
(Fig. 3d–f). This difference was statistically signiﬁcant,
representing a 16% loss of striatal neurons through GSH
depletion compared to control shRNA expression. Since
during the same time period 57% of nigral DA neurons
degenerated, we conclude the latter to be signiﬁcantly more
vulnerable to GSH depletion. We detected no morpholog-
ical differences in striatal neurons expressing control or
GCLc-targeting shRNAs; however, striatal neurons clearly
reacted to a targeting of GSH synthesis in that they dis-
played a substantially reduced (about tenfold) EGFP
ﬂuorescence compared to controls.
Silencing neuronal GSH synthesis induces aggregate
formation and moderate gliosis
Thioﬂavin-S staining for accumulated b-sheet structures
revealed several small and uniformly distributed positive
signals in DA neurons of the SNpc under all conditions
(non-injected, control shRNA expressing and contralateral
nigra, Fig. 4a) but not in DA neurons of the VTA (Suppl.
Fig. 2 Progressive motor impairments develop after silencing of
glutathione synthesis. a Apomorphine-induced turning behaviour was
recorded to monitor functional striatal imbalance in DA transmission.
At 3, 6 and 9 weeks after administration of an AAV vector expressing
a control shRNA (Luc) or GCLc-shRNA#2 (GCLc) the number of
360 rotations to the contralateral side (Con, black bars) or the
ipsilateral side (Ips, grey bars) was quantiﬁed. b After killing of these
animals at 9 weeks after vector administrations, ipsilateral and
contralateral striatal levels of DA, DOPAC, and HVA were measured
by HPLC and are shown as the percentage of ipsilateral versus
contralateral level for control (Luc, grey bars) and GCLc-shRNA#2
(GCLc, dark bars)
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123Fig. 4). After 3 weeks of expression of GCLc-shRNA#2
many DA neurons displayed Thio-S-positive inclusions
just as the controls did (Fig. 4b), but we also detected what
appeared to be a progressive formation of aggregated
material: several DA neurons showed larger Thio-S posi-
tive inclusions (arrow in Fig. 4d) and inclusions within
neurites (Fig. 4c), and some cells already demonstrated
large Thio-S positive bodies (Fig. 4e, f). The latter cells
displayed inhomogeneous or even no TH immunoreactiv-
ity. In no case did we detect fragmented nuclei in the
vicinity of Thio-S accumulations, arguing against a major
contribution of classical apoptosis in the degeneration of
these DA neurons, an assumption strengthened by the near
absence of activated caspases (Suppl. Fig. 6). At 9 weeks
after expression of GCLc-shRNA#2 we mainly detected
large peri-nuclear Thio-S positive structures within sub-
stantia nigra but not in controls (Fig. 4g, h). It should be
noted that we did not detect a-synuclein or ubiquitin
immunoreactivity in these aggregates. Neurites which were
still TH immunoreactive demonstrated large numbers of
substantial swellings (Fig. 4h) after GCLc-shRNA#2
expression, which were almost absent in controls (Fig. 4g).
GSH depletion-initiated neurodegeneration was accom-
panied by glial responses. We detected increased
immunoreactivity for astrocytic GFAP and microglial
CD11b in GCLc-shRNA#2 transduced nigrae (Suppl.
Fig. 5b, d) compared to control shRNA-expressing nigrae
(Suppl. Fig. 5a, c). All CD11b-positive microglial cells
presented ramiﬁed morphology, we did not detect cells
which had differentiated into macrophages.
a-Synuclein partially protects from GSH-depletion-
induced neurodegeneration
In rodents the AAV-2-mediated over-expression of a-syn-
uclein-A53T results in a slowly progressive degeneration
of the nigro-striatal projection, with signiﬁcant impact on
axonal and synaptic functionality but without overt loss of
DA cell bodies at 9 weeks after vector application [5]. This
delayed degeneration is most probably due to the fact that
for rodents’ threonine at position 53 represents the wild-
type amino acid. In order to investigate if such moderate
a-synuclein-mediated neurotoxicity would aggravate
degeneration of DA neurons initiated by GSH depletion,
we co-expressed a-synuclein-A53T together with either
a control shRNA or GCLc-shRNA #2 in DA neurons.
a-Synuclein-A53T co-expression with the control shRNA
did not result in loss of DA neurons while GCLc-shRNA
#2 expression alone resulted in pronounced DA neuron
loss. Unexpectedly, we detected a moderate but signiﬁcant
protection from DA neuron loss by co-expression of
a-synuclein-A53T with GCLc-shRNA #2, demonstrating
Fig. 3 Nigral DA neurons are
selectively vulnerable to
glutathione depletion.
Transduction of SNpc (a, b) and
striatum (d, e) by AAV vectors
expressing control shRNA (a,
d) or GCLc-shRNA#2 (b, e).
Pictures are shown as overlays
of EGFP ﬂuorescence (green)
with TH immunoreactivity (a,
b) or NeuN immunoreactivity
(d, e)( red) and nuclear DAPI
stain (blue). High magniﬁcation
insets in a and b are taken from
areas inside the SNpc (i) and
outside the SNpc (parabrachial
pigmented nucleus, substantia
nigra pars reticulate) (ii). Scale
bars are 250 lmi n( a,
b) (50 lmi ninsets) and
100 lmi n( d, e). Note that
exposure times for EGFP were
1,000 ms in d, but 4,000 ms in
e. Quantiﬁcation of EGFP(?)/
TH(-) neurons in SNpc is
shown in c, quantiﬁcation of
EGFP-positive neurons in
striatum after control (ﬂuc-
shRNA) or targeting of GSH
synthesis (GCLc-shRNA#2) are
shown in f as mean ± SD
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123that at least under the experimental conditions used in this
study a-synuclein can protect DA neurons from GSH
depletion-initiated degeneration (Fig. 5a).
Over-expression of GCLc or GCLm leads to aberrant
glutathiolation of neuronal proteins and induces
neurodegeneration
We furthermore set out to perform a rescue experiment, in
which a shRNA can downregulate expression of its cellular
target protein, but a non-targetable ‘‘rescue protein’’ is co-
expressed to restore the RNAi-induced phenotype. Such a
rescue protein has the same amino acid sequence as its
cellular counterpart, but is coded by a cDNA in which the
binding site for the shRNA is eliminated by nucleotide
exchanges. Enhancement of GSH production obtained
through over-expression of these rescue proteins was
quantiﬁed in cultured neurons and demonstrated that a
moderate increase in GSH was obtained from over-
expression of the human GCLm (120% of control), while
about 2.2-fold more GSH than in controls was produced by
over-expression of the GCLc-rescue protein. Co-expression
of both proteins resulted in approximately threefold higher
levels of GSH (Fig. 5b). The respective rescue proteins
were then co-expressed in substantia nigra together with
shRNAs targeting the endogenous GCLc (GCLc-
shRNA#2) or GCLm (GCLm shRNA#1). Surprisingly, we
did not ﬁnd any amelioration of DA neuron death through
this rescue approach (data not shown). The unravelling of
this paradox came from the ﬁnding that over-expression of
both subunits of GCL per se, in the absence of any shRNA,
induced degeneration of DA neurons (Fig. 5c, d; Table 1 in
Supplement). We detected large numbers of distorted
neurites emanating from surviving DA neurons, presenting
with pearl necklace-like swellings. These swellings stained
for TH but also for GSH adducts on proteins, indicating an
aberrant glutathiolation of cellular proteins (Fig. 5e–n).
These results indicated that even relatively moderate
increase of GSH production can serve as a trigger for DA
neuron degeneration, suggesting that GSH levels in nigral
DA neurons must be intimately maintained within a narrow
range.
Discussion
It has long been debated whether GSH depletion as found in
PD patients’ substantia nigra is a cause or a consequence of
DA neuron degeneration, and if DA neurons would indeed
be speciﬁcally vulnerable to GSH depletion. Targeting of
the catalytic subunit of the rate-limiting enzyme in GSH
synthesis, glutamate–cysteine ligase (GCLc) has been the
traditional approach to elucidate this issue. Pharmacologi-
cal inhibition by infusion of the GCLc inhibitor buthionine
sulfoxamine (BSO) into the adult rat brain did not induce
degeneration of DA neurons [35]. While constitu-
tive knock-out of GCLc was embryonically lethal [7], a
conditionally GCLc anti-sense RNA-expressing mouse
demonstrated oxidative damage of mitochondrial complex I
as a consequence of GSH depletion and showed a minor
loss of DA neurons in aged animals [4]. However, given the
possible off-target effects of expression of the anti-sense
RNA and the lack of any control for such effects [1], this
model must be considered with caution. Furthermore, no
effects of GSH depletion in non-DA neurons could be
assessed, and no behavioural readout could be obtained. We
now demonstrate that by an RNAi-mediated approach we
could unequivocally induce progressive DA neuron
degeneration by targeting the expression of GCLc or
Fig. 4 Accumulation of Thioﬂavin-S-positive protein aggregates in
nigral DA neurons. Confocal Z-stacks covering a depth of 15 lm
were recorded and combined into a single image, showing Thio-S
stain in green, TH immunoreactivity in red and nuclear DAPI stain in
blue. Images were recorded at three (a–f) or 9 weeks after transduc-
tion (g, h). Arrowheads in c point to neuritic inclusions, arrow in
d points to larger cytoplasmic inclusion. In g neurite architecture is
intact, while predominantly swollen neurites are seen in h. Scale
bar 5 lmi na–f and 20 lmi ng, h
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123GCLm. While nigral DA neurons degenerated progres-
sively over time in a pace depending on potency of the
respective shRNA to decrease GSH levels as determined in
vitro, extra-nigral non-DA neurons and striatal neurons
were apparently less vulnerable. This ﬁnding contradicts
data obtained from cultured dopaminergic neurons, which
Fig. 5 a-Synuclein partially
prevents GSH-induced
degeneration and
overproduction of GSH induces
degeneration of nigral DA
neurons. Quantiﬁcation of nigral
dopaminergic neurons after co-
expression of a-synuclein with
control shRNA or GCLc-
targeting shRNA is shown in
a. GSH overproduction in
cultured neurons was quantiﬁed
after transduction with AAV
vectors expressing a control
shRNA, the catalytic or the
modulatory subunit of GCL, or
both subunits together (b).
Quantiﬁcation of SNpc TH?
(c) or VMAT-2? (d) cells is
shown at 9 weeks after
transduction with AAV
vectors expressing GCLm
or GCLc constructs.
Immunohistochemistry for
GSH-protein adducts (e–g), TH
(h, j, k) and their superposition
with nuclear DAPI stain
(l–n) are shown in tissue
sections obtained at 9 weeks
after transduction with a control
vector (an AAV expressing
no transgene, empty vector),
AAV-GCLc or AAV-GCLm
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123were more resistant to BSO application than non-dopami-
nergic midbrain neurons [26]. In AAV-GCLc-shRNA#2
transduced striatal neurons we found an almost tenfold
reduction of ﬂuorescence of the EGFP reporter compared to
controls, which might be explained by the strong quenching
of the EGFP ﬂuorophore by reactive oxygen species like
singlet oxygen derived from lipid peroxidation [11] under
conditions of depleted anti-oxidant defence capabilities.
This quenching of the EGFP reporter co-expressed with the
GCLc-targeting shRNA demonstrates substantial impact on
striatal neuron physiology, which, however, degenerated to
a much lesser extent than nigral DA neurons. These results
for the ﬁrst time suggest a selective vulnerability of DA
neurons towards depletion of anti-oxidant defence, which
might be an explanation for their preferential death in PD
patients.
GSH depletion induced an apparent continuum of for-
mation of Thio-S positive aggregate structures within
affected DA neurons. The morphology of these aggregates
resembled the so-called pale bodies (PB) which are thought
to be a precursor stage of Lewy bodies (LB), and the
obvious morphogenesis of these structures recapitulates the
human pathology revealed by immunohistochemical
methods in postmortem tissue [21]. However, since they
are negative for a-synuclein and ubiquitin immunoreac-
tivity, their composition appeared to be quite different from
Lewy bodies. Thus, while GSH depletion can be a selective
trigger for DA neurons to degenerate, further impacts must
occur in patients to cause a-synuclein aggregation.
Intriguingly, our attempts to foster GSH-induced degener-
ation by over-expression of the familial a-synuclein mutant
A53T demonstrated that a-synuclein partially ameliorated
DA neuron survival. It should be emphasized that for
rodent a-synuclein T53 is the wild-type amino acid, and
that AAV-2-mediated over-expression of a-synuclein-
A53T in the rat nigra did not result in DA cell body loss at
9 weeks in an independent study [5]. Thus, this protection
may not be representative for other a-synuclein mutants or
more enforced expression of a-synuclein. However, this
ﬁnding is reminiscent of a-synuclein’s neuroprotective
effect in CSP-a-deﬁcient mice [2], which is mediated
through interaction with synaptic vesicles. Together with
the early appearance of ipsilateral rotation behaviour and
the prevalence of Fluoro-Jade positive neurites rather than
cell bodies, protection achieved by a-synuclein suggest that
GSH-depletion-induced neurodegeneration might be initi-
ated at synaptic or axonal sites.
While it has been demonstrated in vitro and in vivo that
depletion of GSH leads to nitric oxide-mediated oxidative
damage of mitochondrial complex I components [4, 8], the
mechanism of neuronal cell loss is less clear. Cultured
cortical neurons which were depleted by GCLc or GCLm
demonstrated features of apoptotic cell death [8], but in
concordance with results obtained in postmortem tissue
[22], we did not detect signiﬁcant activation of caspases in
nigral DA neurons and no fragmented nuclei by GSH
depletion. Activation of astrocytes was moderate, while
staining for activated microglia showed more robust
increase, as seen in postmortem PD brains [14]. However,
microglia morphology remained ramiﬁed and no cells with
spherical macrophage-like shape appeared, indicating that
classical necrosis might not be a prominent feature of DA
neuronal death after GSH depletion.
GSH depletion induced a progressive decline in motor
control, allowing us to follow the degeneration of the ni-
gro-striatal system by simple behavioural assessment.
Thus, this animal model is well suited for testing drugs
aimed at protecting DA neurons from degeneration in
functional assays, with the option to be transferred to brains
of non-human primates. As it is based on a patho-physio-
logical principle detected in brains of sporadic PD patients,
it may be a valuable alternative to toxin-based models of
PD currently employed, since compounds tested success-
fully in MPTP and 6-OHDA models have met with very
limited beneﬁt in clinical trials [17].
Increase of GSH production by GCLc over-expression
was protective against oxidative stress in cultured cortical
neurons [8]. The obvious strategy to increase GSH pro-
duction in DA neurons as a means to protect them from
degeneration, however, led to signiﬁcant cell death in our
in vivo study, presumably due to formation of GSH
adducts on cellular proteins as detected by a GSH-adduct-
speciﬁc antibody. In recent years, it has become evident
that GSH has important functions besides its reducing
activity. In general, thiolation or dethiolation of cellular
proteins by GSH may either increase or decrease their
levels of activity or binding to other cellular structures [6,
36, 37]. Speciﬁcally within the CNS, GSH has been
demonstrated to be able to modify NMDA receptor
activity and leukotriene metabolism, and thus is directly
involved in neuromodulatory events [9, 15]. Due to the
overriding GSH content of astrocytes it is not possible to
reliably quantify the extent to which GSH was reduced or
elevated in individual neurons in vivo, but in cultured
neurons over-expressing either the regulatory or the cata-
lytic subunit of GCL we measured only moderate
increases in GSH levels, in the range of 1.5- to 2.5-fold to
controls. Thus, our results suggest that even relatively
moderate increases in GSH can initiate degeneration of
DA neurons, arguing against delivery of GCLc or GCLm
to the brain, e.g. by gene therapeutic attempts, as a
potential treatment strategy for PD.
In conclusion, our results demonstrate the distinct
dependence of nigral DA neurons on tight control of GSH
levels, suggesting that disturbed GSH homeostasis can be a
trigger in the initiation of DA neuron degeneration in PD.
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